Abstract:Introduction Both mycophenolate mofetil (MMF) and intravenous cyclophosphamide (CYC) have been recommended in the induction therapy of lupus nephritis (LN) for years; nevertheless, their effectiveness and safety in a real-world setting are extremely lacking. Therefore, we decided to conduct this real-world study. Methods A total of 195 Chinese patients with LN who were initially treated with MMF ( n = 98), or intravenous CYC ( n = 97) as induction therapy were enrolled. All of the patients were followed up to 12 months. Complete renal remission (CRR) was defined as 24-h urinary protein (24 h-UTP) < 0.5 g, and partial renal remission (PRR) was defined as ≥ 50% reduction in 24 h-UTP to the subnephrotic level, however > 0.5 g, both with a change of serum creatinine (SCr) within 10% from baseline. The proportions of CRR, PRR, and total renal remission (TRR), as well as adverse events, were compared by Chi-square test and Kaplan–Meier analysis (log-rank test). Inverse probability of treatment weighting (IPTW) was used for propensity score matching and multivariable logistic regression analyses were employed. Results The cumulative proportion of TRR in 6 months (79.4 vs. 63.8%, p = 0.026) and CRR in 12 months (72.8 vs. 57.6%, p = 0.049) in MMF group were significantly higher than CYC group, and the above conclusions were further confirmed by IPTW. The proportions of PRR, CRR, and TRR at other time points were equivalent between two groups. Further subgroup analysis in 111 patients with biopsy-proven III–V LN also showed a significantly higher proportion of TRR at 6 months in the MMF group than in the CYC group (78.3 vs. 56.9%, p = 0.026). In the Kaplan–Meier analysis and after IPTW, the MMF group showed better TRR and CRR responses than CYC group in 12 months. Multivariable logistic regression analyses revealed that MMF use was the only predictor of CRR (HR 2.12, 95% CI 1.90–4.09, p = 0.026), while low complement level was also a predictor, albeit risk was reduced (HR 0.38, 95% CI 0.17–0.86, p = 0.019). Moreover, compared to the CYC group, MMF group patients were more likely to have significantly lower SCr (μmol/l) [72.5 (62.5, 86.5) vs. 79.0 (71.1, 97.5), p = 0.001] and daily dose of prednisone (mg/day) (15.7 ± 5.2 vs. 18.6 ± 11.3, p = 0.022) at 6 months; lower 24 h-UTP (g) [0.1 (0.1, 0.3) vs. 0.2 (0.1, 0.9), p = 0.005] and daily dose of prednisone (mg/day) (9.6 ± 3.3 vs. 11.2 ± 5.5, p = 0.023) at 12 months. Infection was the most common adverse event. Pneumonia and gastrointestinal discomfort were more frequently observed in the CYC group. Conclusions Real-world data are a key component of the evidence supporting the effectiveness of drugs and are of interest to all stakeholders. Our comparative study demonstrated the effectiveness of MMF in LN induction therapy was at least equivalent to intravenous CYC, with superior tolerance.

Mycophenolate mofetil in the treatment of Chinese patients with lupus nephritis A PRISMA-compliant meta-analysis

Mycophenolate Mofetil in Induction and Maintenance Therapy of Severe Lupus Nephritis: a Meta-Analysis of Randomized Controlled Trials.

Mycophenolate Mofetil for Proliferative Lupus Nephritis: A Systematic Review

Mycophenolate Mofetil Treatment for Diffuse Proliferative Lupus Nephritis: a Multicenter Clinical Trial in China.

Comparison of the Effectiveness and Safety of Mycophenolate Mofetil and Cyclophosphamide in Lupus Nephritis: Evidence from a Real-World Study

Efficacy and long-term prognosis of mycophenolate mofetil treatment on patients with proliferative lupus nephritis

Clinical observations of mycophenolate mofetil therapy in refractory primary nephrotic syndrome.

Evaluation of the efficacy of mycophenolate mofetil treatment in lupus nephritis

Multitarget Therapy for Induction Treatment of Lupus Nephritis A Randomized Trial

Mycophenolate mofetil (MMF) used for treating type Ⅳ lupus nephritis and literature review

Three-year Follow-up Study of Lupus Nephritis Treated with Mycophenolate Mofetii

Efficacy and Safety of Cyclophosphamide Combined with Mycophenolate Mofetil for Induction Treatment of Class IV Lupus Nephritis.

The combination of mycophenolate mofetil with corticosteroids induces remission of Henoch-Schönlein purpura nephritis.

Mycophenolate Mofetil and New-Onset Systemic Lupus Erythematosus: A Randomized Clinical Trial

Network Meta-analysis of long-term usage of different immunosuppressants combined with glucocorticoids in the treatment of systemic lupus erythematosus nephritis

Treatment of Patients with IgA Nephropathy: Evaluation of the Safety and Efficacy of Mycophenolate Mofetil

Pilot 24 Month Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis with Nephrotic Syndrome.

Mycophenolate Mofetil or Tacrolimus Compared with Intravenous Cyclophosphamide in the Induction Treatment for Active Lupus Nephritis

Efficacy and Safety of Mycophenolate Mofetil in Patients with IgA Nephropathy: an Update Meta-Analysis

Mycophenolate Mofetil in the Treatment of Primary Nephrotic Syndrome

Mycophenolate Mofetil Versus Intravenous Pulse Cyclophosphamide for Class Ⅳ Plus Ⅴ Lupus Nephritis